Symptom profiles and health care utilization in long-term survivors of Survivors of Childhood Childhood Cancer Survivor (CCSS) study.

Authors

null

Rachel Tillery Webster

St. Jude Children's Research Hospital, Memphis, TN

Rachel Tillery Webster , Wei Liu , Meghan Eileen McGrady , Nicole M. Alberts , Tara M. Brinkman , Kirsten K. Ness , Bernard Fuemmeler , Alicia Kunin-Batson , Deokumar Srivastava , I-Chan Huang , Gregory T. Armstrong , Rebecca M. Howell , Daniel M. Green , Yutaka Yasui , Kevin R. Krull

Organizations

St. Jude Children's Research Hospital, Memphis, TN, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, Concordia University, Montreal, QC, Canada, Virginia Commonwealth University, Richmond, VA, University of Minnesota Medical School, Minneapolis, MN, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Funding

U.S. National Institutes of Health
American Lebanese-Syrian Associated Charities (ALSAC)

Background: Physical and psychological symptoms co-occur among survivors of childhood cancer, and subgroups with high symptom burden may be at increased risk for problematic healthcare utilization (HCU). Methods: Childhood Cancer Survivor Study participants (N = 17,231; Mean [SD] age = 27.4 [5.98]; 79% non-Hispanic White; 48% female) self-reported sensory, motor, cardiac, respiratory, pain, gastrointestinal, fatigue, memory, depression, and anxiety symptoms at baseline evaluation and latent class analysis identified symptom profiles. Chronic health conditions (CHCs) at baseline (graded per CTCAE 1-2 [mild or moderate; reference] vs 3-4 [severe-life threatening or disabling). HCU (no health care, general care, oncology-focused, long-term follow-up, emergency room visit) for the past 2 years was assessed 6.3 median years after baseline. Logistic regressions examined associations between class membership and follow-up HCU, adjusted for sex, age, health insurance and CHCs. Results: Five symptom classes were identified: 1) Global symptoms (global; 7.7%); 2) emotional distress and pain (distress-pain; 13.3%); 3) neurologic and pain (neuro-pain; 10.6%); 4) cardiopulmonary and pain (cardio-pain; 5.3%); 5) non-elevated symptoms (norm; 63.1%). Bone tumor survivors had higher risk of falling into global, neuro-pain and cardio-pain groups (p’s < .001), and CNS tumor survivors had higher risk of falling into global and neuro-pain group (all p < .001) compared to leukemia survivors. Radiation, Grade 3-4 CHCs, female sex, and older age increased risk of global, distress-pain, neuro-pain and cardio-pain membership compared to norm (all p’s < .001). Oncology-focused care was more common in cardio-pain and global symptom groups, while long-term follow-up care was more common in neuro-pain and global groups (Table). All elevated symptoms groups were more likely to have emergency room visits compared to norm group. Conclusions: Adjusting for insurance, CHCs and older age, elevated symptoms are associated with future emergency room use. Pain is prevalent in all high symptom groups, and suggests an important intervention target.

Symptom Class
No Health Care
Oncology-Focused
Long-term Follow-up
Emergency Room
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
Norm
Ref
ref
ref
ref
Distress-Pain
.88 (.73, 1.08)
.94 (.78, 1.15)
1.06 (.88, 1.27)
1.42 (1.27, 1.59)
Cardio-Pain
.82 (.58, 1.17)
1.41 (1.08, 1.85)
1.08 (.80, 1.44)
1.52 (1.30, 1.78)
Neuro-Pain
1.18 (.95, 1.46)
.94 (.75, 1.18)
1.30 (1.06-1.59)
1.36 (1.20, 1.54)
Global
1.05 (.80, 1.37)
1.34 (1.05, 1.71)
1.37 (1.09, 1.74)
1.82 (1.61, 2.06)

Odds Ratio (OR) and 95% confidence intervals (CI) predicting health-care utilization vs general health care by symptom class. Models adjusted for age, sex, health insurance and CHCs.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Survivorship

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e22024)

DOI

10.1200/JCO.2022.40.16_suppl.e22024

Abstract #

e22024

Abstract Disclosures